Thursday, Nov 4, 2004
South San Francisco, Calif. -- November 4, 2004 --Genentech, Inc. (NYSE: DNA) today announced two senior appointments in the company's Manufacturing and Engineering organizations: Markus Gemuend as vice president, Manufacturing Collaborations and Contract Manufacturing, and Timothy Moore as vice president, Corporate Engineering.
Manufacturing Collaborations and Contract Manufacturing
Markus Gemuend, 46, joins Genentech as vice president, Manufacturing Collaborations and Contract Manufacturing, reporting to Philippa Norman, vice president, Global Supply Chain. In this newly created role, Gemuend will be responsible for managing Genentech's outsourcing strategies for bulk manufacturing, filling and packaging, and directing the management of supply relationships with Genentech's commercial partners.
"As Genentech strengthens its manufacturing strategies to support the growing demand for our life-improving and life-extending therapies for patients, Markus' leadership and experience in the pharmaceutical and biotech contract manufacturing industry will be important to our efforts," stated Norman. "Markus brings to Genentech a proven track record of leading successful business initiatives in a complex and competitive commercial arena."
Gemuend joins Genentech from Lonza Group Ltd., Basel, Switzerland, where he held the position of chief executive officer from 2002 to 2004. During his 16 years at Lonza, Gemuend held several leadership roles, including senior vice president and sector head for Lonza Biologics as well as vice president of Exclusive Synthesis US. Gemuend joined Lonza in 1988 as legal counsel.
Gemuend holds a law degree from the University of Basel, Switzerland.
Timothy L. Moore
Timothy L. Moore, 43, joins Genentech as vice president, Corporate Engineering. Moore will lead the development and implementation of engineering projects that support Genentech's growth, including the development of compliant and robust manufacturing systems, equipment and facilities. Moore reports to Patrick Y. Yang, Ph.D., vice president, South San Francisco Manufacturing and Engineering.
"Tim has extensive experience in pharmaceutical engineering and operations which will help us continue to build a world-class engineering group in support of our growth," said Yang. "His excellent leadership skills and results-oriented capabilities will contribute to the success of our manufacturing and engineering projects."
Moore most recently held the position of vice president, Operations at ZLB Behring (formerly Aventis Behring) where he managed aseptic/biological manufacturing operations. Moore brings over 20 years of experience in the pharmaceutical/biological industry including engineering experience at Merck & Co.
Moore holds a bachelor's degree in Chemical Engineering from the University of Tulsa and a master's degree in Engineering Management from Northwestern University.
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States and licenses several additional products to other companies. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.